- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
17 result(s) found for: Distance correlation.
Displaying page 1 of 1.
EudraCT Number: 2011-006152-36 | Sponsor Protocol Number: 1774 | Start Date*: 2012-05-10 | |||||||||||
Sponsor Name:Middelfart Rygsektor | |||||||||||||
Full Title: Postoperative treatment with parathyroidea hormone Forteo® in patients undergoing posterolateral spinal fusion surgery. A prospektive and a randomized double-blinded, placebo-controlled study | |||||||||||||
Medical condition: Spinal stenosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002616-16 | Sponsor Protocol Number: NL49061.031.14 | Start Date*: 2014-07-10 |
Sponsor Name:NKI-AVL | ||
Full Title: Pilot for high-resolution SPECT imaging of breast cancer lumpectomy specimens for 3D identification and quantification of resection margins | ||
Medical condition: Patients with breast cancer, IDC (n=3) and DCIS (n=3) scheduled for a lumpectomy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000106-35 | Sponsor Protocol Number: GX29185 | Start Date*: 2015-02-02 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDAR... | |||||||||||||
Medical condition: Geographic atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) AT (Completed) DK (Prematurely Ended) GB (Prematurely Ended) SE (Completed) NL (Prematurely Ended) ES (Completed) BE (Prematurely Ended) PT (Prematurely Ended) SK (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000107-27 | Sponsor Protocol Number: GX29176 | Start Date*: 2015-02-02 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDAR... | |||||||||||||
Medical condition: Geographic atrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended) AT (Completed) DK (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended) NL (Prematurely Ended) SK (Completed) ES (Completed) BE (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001338-32 | Sponsor Protocol Number: NFPA12 | Start Date*: 2012-09-24 | |||||||||||
Sponsor Name:St. Olavs Hospital Trondheim University Hospital | |||||||||||||
Full Title: Dopamine agonist treatment of non-functioning pituitary adenomas (NFPAs) - a randomized controlled trial. The efficacy of cabergoline on tumour volume in previously untreated macroadenomas or resid... | |||||||||||||
Medical condition: non-functioning pituitary adenomas | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024391-25 | Sponsor Protocol Number: 2010CLI01 | Start Date*: 2011-05-11 |
Sponsor Name:XCell-Center GmbH | ||
Full Title: A Multi-centre, double blind, randomized placebo controlled phase II study to assess the efficacy and safety of ASCT01 in Critical limb Ischemia Patients - SCILI | ||
Medical condition: Critical Limb Ischemia Rutherford clas 4-6 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004782-24 | Sponsor Protocol Number: PRM-151-202 | Start Date*: 2016-03-01 | |||||||||||
Sponsor Name:Promedior, Inc. | |||||||||||||
Full Title: A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF) | |||||||||||||
Medical condition: Idiopathic Pulmonary Fibrosis (IPF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) CZ (Completed) ES (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013331-37 | Sponsor Protocol Number: WSG-AM05 | Start Date*: 2011-05-04 | |||||||||||
Sponsor Name:WSG GmbH | |||||||||||||
Full Title: GALADON - Molecular Imaging Response Assessment of Bevacizumab+Docetaxel as Neoadjuvant Chemotherapy in Primary Breast Cancer | |||||||||||||
Medical condition: histologically confirmed locally advanced breast cancer (> cT2); known HER2 status, known ER status | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003786-28 | Sponsor Protocol Number: PERC2015 | Start Date*: 2016-01-19 |
Sponsor Name:Radboudumc | ||
Full Title: Pulmonary NTM disease: A regimen of ethambutol and azithromycin with as adjunctive rifampicin vs clofazimine. | ||
Medical condition: Fibrocavitary pulmonary disease caused by M.avium complex | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005043-13 | Sponsor Protocol Number: RG_14-187 | Start Date*: 2016-08-11 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Evaluating different rate control therapies in permanent atrial fibrillation: A prospective, randomised, open-label, blinded endpoint study comparing digoxin and beta-blockers as initial rate contr... | |||||||||||||
Medical condition: Atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004397-99 | Sponsor Protocol Number: MBCC28040 | Start Date*: 2014-06-17 |
Sponsor Name:Instituto Tecnológico PET, S.A.U. (ITP) | ||
Full Title: A Phase III Clinical Trial to evidence the safety and efficacy of the radio-drug 18f-Fluorocholine (18F-FCH), using Positron Emission Tomography (PET) for the diagnosis of the prostate carcinoma in... | ||
Medical condition: Prostate Carcinoma in patients with biochemical relapse. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-003158-21 | Sponsor Protocol Number: MGNT2022 | Start Date*: 2023-04-17 | |||||||||||
Sponsor Name:Centro Hospitalar de Trás-os-Montes e Alto Douro (CHTMAD), EPE | |||||||||||||
Full Title: MAGNETICAL: MAGNetic resonance Evaluation of Tafamidis Impact in Cardiac AmyLoidosis | |||||||||||||
Medical condition: TTR amyloidosis (wild type or hereditary) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002333-29 | Sponsor Protocol Number: GEMCAD-1601 | Start Date*: 2017-04-19 | |||||||||||
Sponsor Name:GEMCAD (Grupo Español Multidisciplinar en Cáncer Digestivo) | |||||||||||||
Full Title: Preoperative induction therapy with 12 weeks of Panitumumab in combination with mFOLFOX-6 in an enriched population (Quadruple Wild-Type) of patients with mrT3 rectal cancer of the middle third wit... | |||||||||||||
Medical condition: Patients with rectal adenocarcinoma of intermediate risk (defined by magnetic resonance imaging [MRI]), without mutations in KRAS, BRAF, NRAS and PI3KCA, who are candidates for preoperative treatment. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002677-22 | Sponsor Protocol Number: TVECUSDoppler | Start Date*: 2020-02-05 |
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | ||
Full Title: Doppler sonography of skin and nodal metastases as a predictor of clinical response to Talimogene Laherparepvec (T-VEC) in melanoma patients (T-VEC – US Doppler) | ||
Medical condition: Melanoma stage IIIB-IVM1a | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004412-22 | Sponsor Protocol Number: U-2013-007 | Start Date*: 2014-12-12 | |||||||||||
Sponsor Name:UCR Uppsala Clinical Research Center | |||||||||||||
Full Title: TRIAL OF CAFFEINE TO ALLEVIATE DYSPNEA RELATED TO TICAGRELOR (TROCADERO) A double-blinded, placebo-controlled, randomized, multicenter, development phase II study | |||||||||||||
Medical condition: Dyspnea | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004936-13 | Sponsor Protocol Number: GORTEC_2018-01 | Start Date*: 2020-05-26 | |||||||||||
Sponsor Name:GORTEC | |||||||||||||
Full Title: A phase III randomized trial of post-operative adjuvant nivolumab and concomitant chemo-radiotherapy in high-risk patients with resected squamous cell carcinoma of head and neck (SCCHN) | |||||||||||||
Medical condition: Squamous cell carcinoma treated by primary surgery Stage III, stage IV (American Joint Committee on Cancer 7th edition) Oral cavity, oropharynx, hypopharynx or larynx | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001223-49 | Sponsor Protocol Number: PTC124-GD-041DMD | Start Date*: 2018-01-16 | |||||||||||
Sponsor Name:PTC Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension | |||||||||||||
Medical condition: Nonsense Mutation Duchenne Muscular Dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: BG (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
